CONFERENCES
REPORTS
BARNETT EDUCATIONAL SERVICES
CONSULTING
PUBLICATIONS & eNEWSLETTERS
PROFESSIONAL SERVICES
EXECUTIVE TEAM
TESTIMONIALS
CHI TIME LINE
DRUG DISCOVERY MAP
CAREERS
ABOUT CHI
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, and academic organizations. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, lnsight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and Cambridge Healthtech's Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992. Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related in commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.
CONTACT US
CHI Corporate
250 First Avenue
Suite 300
Needham, MA 02494
Click here for directions
Phone: 781-972-5400
Toll-Free: 888-999-6288
Fax: 781-972-5425
Web: www.chicorporate.com
Barnett International
250 First Avenue
Suite 300
Needham, MA 02494
Phone: 781-972-5400
Toll-Free: 800-856-2556
Fax: 781-972-5441
Web:
www.barnettinternational.com
Email:
customer.service@
barnettinternational.com
|
|
|
Professional Services
Our Life Sciences Market Surveys Program offers custom surveys that will help you meet your Market Research needs from design and implementation to the final reporting, we’ve got you covered. Whether you require information to support product development, opportunity assessment,
|
Marketing Our Marketing team consists of 14 experienced professionals knowledgeable in all aspects of event marketing and capable of providing the maximum amount of exposure for your event. A dedicated Marketing Project Manager will work closely with you to create
|
Reports
Author: Lucy J. Sannes, PhD, MBA Executive Summary Chapter 1 Introduction Scope of the Report Chapter 2 Review of Selected Major Solid Tumors Targeted by Pharmaceutical Companies 2.1. Brain Cancer 2.2. Breast Cancer 2.3. Cervical Cancer 2.4. Colorectal Cancer 2.5. Head and Neck Cancer 2.6. Lung Canc
|
|
|
Author: Lucy J. Sannes, PhD, MBA TABLES Table 2.1. Incidence and Mortality of Selected Solid Tumors in the United States, 2011 Table 2.2. Five-Year Relative Survival Rates by Stage of Diagnosis (1999–2006) For Selected Major Cancers Targeted by Pharmaceutical Companies Table 3.1. Selected Chemotherapy Drugs
|
Author: Lucy J. Sannes, PhD, MBA Executive Summary Chapter 1 Introduction Scope of the Report Chapter 2 Review of Selected Major Solid Tumors Targeted by Pharmaceutical Companies 2.1. Brain Cancer 2.2. Breast Cancer 2.3. Cervical Cancer 2.4. Colorectal Cancer 2.5. Head and Neck Cancer 2.6. Lung Canc
|
|
|
Compact Discs & DVDs
May 6-7, 2013 • Philadelphia, PA
|
April 29-30, 2013 • Boston, MA
|
April 9-11, 2013 • Boston, MA
|
February 13-15, 2013 • San Francisco, CA
|
February 13, 2013 • San Francisco, CA
|
Bio-IT
Forbes | Bristol-Myers Squibb's approved drug, Yervoy, is being tested in combination with several experimental drugs to treat advanced melanoma.
|
Tuesday, May 7, 2013 | BIO IT World | Archives | Advertising | CHI Conferences | Subscribe THIS WEEK IN BIO IT WORLD The Model Approach to Drug Development Bio IT World | In a presentation at the Bio IT World Expo last month, Anna Kondic of Merck & Co.
|
Tuesday, April 30, 2013 | BIO IT World | Archives | Advertising | CHI Conferences | Subscribe THIS WEEK IN BIO IT WORLD NIH Seeks New ADDition in a Data Science Director Bio IT World | BETHESDA, MD—With two weeks left to the application deadline, the National Institutes of
|
Tuesday, April 2, 2013 | BIO IT World | Archives | Advertising | CHI Conferences | Subscribe THIS WEEK IN BIO IT WORLD Amgen Mulls Future of deCODE’s Clinical Sequence Miner Platform Bio IT World | BOSTON—An interview with Kari Stefansson, the co founder, CEO, heart and soul
|
Harvard Business Review | Cancer drugs are expensive to make and expensive for patients. Last week 100 cancer specialists published an op ed in Blood claiming that the high cost of drugs is preventing some patients from being treated. But there is a win-win solution.
|
|